Jan Garfinkle

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

Koya Medical is a transformative healthcare company developing breakthrough treatments for venous and lymphatic diseases to increase movement, mobility and personalized care that is unavailable with traditional compression therapy. Koya was founded in 2018 with the mission to transform venous and lymphatic care through innovative patient-centric platforms. We are privately held and proudly located in Oakland, California where we design, develop and manufacture our products. Interested in joining our team? Email us at info@koyamedical.com.

Francis Medical is developing minimally invasive treatment solutions for prostate, kidney, and bladder cancer through the use of convective thermal water vapor. Currently, the company is in clinical trials for ablating cancerous prostate tissue. Founded in 2018, Francis Medical is located in Maple Grove, Minnesota. Francis Medical, Inc., formerly named NxPhase Medical, Inc., is a company that was created after Boston Scientific (BSC) acquired NxThera, Inc. in April of 2018. As a part of the BSC/NxThera transaction, a separate and independent entity, NxPHASE Medical, Inc. (“NxPHASE”), was established, and shares of NxPHASE were distributed to the shareholders of BSC/NxThera. In addition, BSC/NxThera granted NxPHASE a license to utilize BSC/NxThera’s convective vapor ablation technology to develop, evaluate, and commercialize certain devices to treat prostate, kidney and bladder cancer (“NxPHASE Field of Use”), while BSC/NxThera remains focused on the treatment of benign prostatic hyperplasia. Late in 2018, NxPhase Medical, Inc. went through a rebranding process and selected Francis Medical, Inc. as its new brand and identity. The name and foundation of the company are a tribute to and legacy of Michael Hoey’s (founder/inventor) father, Francis Hoey, whose life was ended by prostate cancer with treatments that had harsh implications on his normal daily living. In December 2018, Francis Medical completed an $18.0 million round of Series A financing. In September 2021, the company closed a $55 Million Series B Equity Financing.

Saint Joseph Mercy Health System is committed to providing a remarkable patient experience by using leading edge technology in a comforting and healing environment. Discover Remarkable by learning how we are here for you in the healing of body, mind and spirit. Mission: We, Trinity Health, serve together in the spirit of the Gospel to be a compassionate and transforming healing presence within our communities.

Mission As CommonSpirit Health, we make the healing presence of God known in our world by improving the health of the people we serve, especially those who are vulnerable, while we advance social justice for all. Vision A healthier future for all - inspired by faith, driven by innovation, and powered by our humanity. Values Compassion • Inclusion • Integrity • Excellence • Collaboration Who we are The system provides care to a service area of just over 200,000 individuals. Trinity is accredited by the Joint Commission on the Accreditation of Hospitals, a member of the American Hospital Association, Voluntary Hospitals of America and the Catholic Hospital Association. The system offers a full array of acute and outpatient services on two campuses. Trinity also maintains physician offices, Walk-in Lab Draw facilities, the Tony Teramana Cancer Center, WorkCare and the Digestive and Nutrition Center throughout the Tri-State area. Additionally, at Trinity we understand patient education is a vital role in maintaining a healthy community. Our staff participates in numerous health fairs and blood screening programs throughout the year.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

The NeuMoDx™ Molecular systems are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result.” The NeuMoDx™ 288 and the NeuMoDx™ 96 Molecular systems are fully automated, continuous random-access analyzers that utilize proprietary NeuDry reagent technology, which integrates magnetic particle affinity capture and real time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. This technology, combined with a platform, uniquely incorporates robotics and microfluidics that result in higher throughput, improved performance, and increased efficiency by eliminating the waste associated with technologies that require reconstitution of lyophilized reagents. NeuMoDx™ has recently received FDA 510(k) clearance for its NeuMoDx™ GBS Assay for the detection of Group B Streptococcus (GBS) DNA in antepartum pregnant women and will continue development of tests to detect and monitor sexually transmitted and infectious diseases. Additionally, NeuMoDx™ offers a broad range of general purpose reagents and consumables for use by laboratorians in developing qualitative and quantitative Laboratory Developed Tests (LDTs) for use with the NeuMoDx™ Molecular Systems to detect and amplify DNA and RNA targets. Call 888-301-6639 or email info@neumodx.com.

Founded on the Principle of Better Sleep, Naturally Ebb® is the first, drug-free and smart-technology innovation that uses a proprietary cooling ComfortBand to naturally trigger a neural network response in the brain, which quiets the Racing Mind and helps you to fall asleep faster and sleep better through the night.

Official LinkedIn page for Esperion. Esperion is The Lipid Management Company. Our goal is lipid management for everybody, that’s why we work hard to make our medicines accessible. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. For more information, please visit esperion.com and follow us on Twitter at www.twitter.com/EsperionInc. Community guidelines: https://bit.ly/3vLCGdO

CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients. Due to their small size, durability, and lack of wires and batteries, our sensors are designed to be permanently implanted into the cardiovascular system. Using radiofrequency, or RF, energy, our sensors transmit real-time data to an external electronics module, which then communicates this information to the patient’s physician.

At AtaCor Medical, we envision a new world of cardiac rhythm management. As a result, we are designing innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most. Representing the future of temporary pacing without the risks, costs, and drawbacks of traditional methods, the AtaCor EV Temporary Pacing Lead System is designed to: - Enable reliable, prompt, imaging-free temporary pacing with safe post-procedure ambulation - Eliminate the complications associated with transvenous leads - Eliminate the patient discomfort of transcutaneous pacing The AtaCor EV Temporary Pacing System is under development and not approved for sale in any geography.

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

Leaders across Research, Translational Medicine and the Clinic rely on RareCyte as a one-stop resource for Spatial Biology and Liquid Biopsy solutions. Headquartered in Seattle, WA, RareCyte is an innovative precision biology company that has developed technologies and end-to-end integrated platforms enabling advances in oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. Our highly multiplexed fluorescent imaging systems, reagents and contract services empower investigators to unlock spatial context for key biomarkers and develop therapeutics and companion diagnostics through rare cell analysis.

Koya Medical is a transformative healthcare company developing breakthrough treatments for venous and lymphatic diseases to increase movement, mobility and personalized care that is unavailable with traditional compression therapy. Koya was founded in 2018 with the mission to transform venous and lymphatic care through innovative patient-centric platforms. We are privately held and proudly located in Oakland, California where we design, develop and manufacture our products. Interested in joining our team? Email us at info@koyamedical.com.

Francis Medical is developing minimally invasive treatment solutions for prostate, kidney, and bladder cancer through the use of convective thermal water vapor. Currently, the company is in clinical trials for ablating cancerous prostate tissue. Founded in 2018, Francis Medical is located in Maple Grove, Minnesota. Francis Medical, Inc., formerly named NxPhase Medical, Inc., is a company that was created after Boston Scientific (BSC) acquired NxThera, Inc. in April of 2018. As a part of the BSC/NxThera transaction, a separate and independent entity, NxPHASE Medical, Inc. (“NxPHASE”), was established, and shares of NxPHASE were distributed to the shareholders of BSC/NxThera. In addition, BSC/NxThera granted NxPHASE a license to utilize BSC/NxThera’s convective vapor ablation technology to develop, evaluate, and commercialize certain devices to treat prostate, kidney and bladder cancer (“NxPHASE Field of Use”), while BSC/NxThera remains focused on the treatment of benign prostatic hyperplasia. Late in 2018, NxPhase Medical, Inc. went through a rebranding process and selected Francis Medical, Inc. as its new brand and identity. The name and foundation of the company are a tribute to and legacy of Michael Hoey’s (founder/inventor) father, Francis Hoey, whose life was ended by prostate cancer with treatments that had harsh implications on his normal daily living. In December 2018, Francis Medical completed an $18.0 million round of Series A financing. In September 2021, the company closed a $55 Million Series B Equity Financing.